Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma.
BACKGROUND
Localized scleroderma is characterized by circumscribed fibrotic plaques and may progress to widespread skin involvement and fibrosis. Interferon gamma (IFN-gamma) has been shown to be a potent inhibitor of collagen synthesis and of the migration and proliferation of dermal fibroblasts.


OBJECTIVE
Our purpose was to determine whether IFN-gamma is effective in the treatment of localized scleroderma.


METHODS
A double-blind, randomized, placebo-controlled, multicenter study was conducted. Twenty-four patients with progressive lesions received 100 micrograms of IFN-gamma or placebo subcutaneously on 5 consecutive days for 2 weeks followed by 100 micrograms of IFN-gamma or placebo once weekly for 4 weeks. Thereafter patients were observed for 18 weeks. To determine whether improvement could be related to an altered level of collagen messenger RNA (mRNA), biopsy specimens were taken from uninvolved and involved skin before and after therapy.


RESULTS
The patients treated with IFN-gamma or placebo showed no significant difference in size or fibrosis of lesions or collagen type I mRNA synthesis. However, a reduction in the number of new lesions was observed in the IFN-gamma-treated group. The biopsy specimens obtained from involved skin showed a moderate increase of type I collagen and a significant decrease in the small proteoglycan decorin mRNA levels.


CONCLUSIONS
The results indicate that IFN-gamma is ineffective in the treatment of localized scleroderma, but may inhibit the development of new lesions.
Hunzelmann
N
N
Department of Dermatology, University of Cologne, Germany.
Anders
S
S
Fierlbeck
G
G
Hein
R
R
Herrmann
K
K
Albrecht
M
M
Bell
S
S
Muche
R
R
Wehner-Caroli
J
J
Gaus
W
W
Krieg
T
T
D003094:Collagen / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007371:Interferon-gamma / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000032:analysis; D012594:Scleroderma, Localized / Q000378:metabolism / Q000628:therapy*; D012867:Skin / Q000378:metabolism
D012333:RNA, Messenger; D007371:Interferon-gamma; D003094:Collagen